Common Gastrointestinal Concerns Both dual and triple agonists share a class-wide side effect profile dominated by gastrointestinal issues, primarily: Nausea Diarrhea or Constipation Vomiting These effects are dose-related and typically peak during the dose-escalation phase
GLP-1s dramatically reduce appetite and increase satiety
Doses for type 2 diabetes can vary from 2.5 mg weekly up to 15 mg, although high doses are generally uncommon
This stands in stark contrast to the average weight loss seen with GLP-1 medications , which often ranges from 10 to 20 percent of body weight depending on the specific drug and dose
Faghris comprehensive research portfolio encompasses the study of occupational health and safety, examining workplace stressors and their impact on chronic diseases such as mental health issues, cardiovascular conditions, obesity, and type 2 diabetes
The clinical rule is simple: if a patient may be hypoglycemic, provide glucose